Avrobio (NASDAQ:AVRO) Downgraded by ValuEngine to “Sell”
A number of other research analysts also recently issued reports on AVRO. Janney Montgomery Scott reaffirmed a buy rating on shares of Avrobio in a research report on Friday, November 8th. Nomura assumed coverage on shares of Avrobio in a research report on Monday, October 28th. They issued a buy rating and a $35.00 price objective on the stock. Zacks Investment Research raised shares of Avrobio from a sell rating to a hold rating in a research report on Tuesday, November 12th. Finally, HC Wainwright reaffirmed a buy rating and issued a $35.00 price objective on shares of Avrobio in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. Avrobio has an average rating of Buy and an average price target of $30.57.
Shares of Avrobio stock opened at $22.78 on Friday. The firm’s 50 day moving average price is $20.12 and its 200-day moving average price is $17.84. Avrobio has a 52-week low of $11.85 and a 52-week high of $28.52. The company has a market cap of $721.37 million, a P/E ratio of -8.66 and a beta of 2.76.
A number of large investors have recently added to or reduced their stakes in AVRO. Tang Capital Management LLC purchased a new stake in Avrobio during the 3rd quarter worth approximately $11,707,000. Orbimed Advisors LLC grew its position in Avrobio by 438.4% during the 3rd quarter. Orbimed Advisors LLC now owns 570,700 shares of the company’s stock worth $8,058,000 after purchasing an additional 464,700 shares during the last quarter. State Street Corp grew its position in Avrobio by 150.0% during the 3rd quarter. State Street Corp now owns 644,592 shares of the company’s stock worth $9,102,000 after purchasing an additional 386,724 shares during the last quarter. Eventide Asset Management LLC grew its position in Avrobio by 40.5% during the 3rd quarter. Eventide Asset Management LLC now owns 1,305,307 shares of the company’s stock worth $18,431,000 after purchasing an additional 376,416 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Avrobio by 33.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 808,235 shares of the company’s stock worth $13,142,000 after purchasing an additional 203,484 shares during the last quarter. 77.79% of the stock is currently owned by institutional investors.
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Recommended Story: Why do earnings reports matter?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.